On January 13th, Zhongzheng Intelligent Finance News Junshi Biotechnology (688180) announced that its controlling subsidiary, Shanghai Wangshi Biopharmaceutical Technology Co., Ltd., has obtained approval from the National Medical Products Administration to switch from conditional approval to routine approval for the listing of its drug, deuterium hydrobromide remdesivir tablets.

Deuteromidevir hydrobromide tablet is used to treat mild to moderate novel coronavirus infection in adult patients (COVID-19 for short).

The research results show that in mild to moderate COVID-19 patients, deuterium hydrobromide remdesivir tablets can significantly accelerate symptom relief and disappearance, shorten the course of the disease, accelerate virus seroconversion, reduce the incidence of severe COVID-19 or all-cause mortality, and have a more significant effect on elderly and high-risk patients. In patients with mild to moderate liver and kidney dysfunction, this drug has shown good safety and tolerability, and patients do not need or only need to adjust the dosage slightly during the medication process.

At the same time, pharmacological studies have shown that deuterium hydrobromide remdesivir tablets have virtually no drug interactions, greatly reducing medication contraindications and effectively ensuring patients' concomitant use, providing a safer and more effective option for special populations.

This drug will be temporarily included in the scope of medical insurance payment from January 2023, and will be included in the official national medical insurance catalog from January 2024.

The announcement stated that the company will actively promote the above-mentioned projects and strictly comply with relevant regulations to timely fulfill information disclosure obligations regarding the subsequent progress of the projects.